首页 > 市场调查报告书 > 製药

疫苗感染疾病

市场调查报告书

商品编码

1517785

脑膜炎双球菌疫苗市场 - 全球产业规模、份额、趋势、机会和预测，按类型（结合物、多醣、组合、其他）、年龄组（婴儿、儿童和成人）、地区和竞争细分，2019-2029F

Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate, Polysaccharide, Combination, Others), By Age Group (Infant, Children & Adult), By Region and Competition, 2019-2029F

出版日期: 2024年07月21日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年全球脑膜炎双球菌疫苗市场估值为34.5亿美元，预计到2029年预测期内将稳定成长，复合年增长率为5.64%。、结合疫苗和联合疫苗。其中，结合疫苗因其持久的免疫力和提供群体免疫的能力而占据最大的市场份额。组合疫苗也因其在免疫计划中的便利性、减少所需注射次数而受到关注。

市场概况
预测期	2025-2029
2023 年市场规模	34.5亿美元
2029 年市场规模	47.4亿美元
2024-2029 年复合年增长率	5.64%
成长最快的细分市场	组合
最大的市场	北美洲

有几个因素正在推动脑膜炎双球菌疫苗市场的成长。最重要的是全球范围内脑膜炎球菌疾病的盛行率不断上升。各地疫情爆发凸显了有效疫苗接种的必要性，促使各国政府和卫生组织提高免疫覆盖率。

此外，疫苗开发的技术进步导致了更有效、更安全的疫苗的推出。基于蛋白质的疫苗和涵盖多个血清群的结合疫苗等创新显着改善了对脑膜炎双球菌疾病的保护。此外，将脑膜炎双球菌疫苗纳入各国的国家免疫计画也促进了市场成长。

儘管前景乐观，脑膜炎双球菌疫苗市场仍面临一些挑战。疫苗开发和生产的高成本可能会限制疫苗的取得，特别是在低收入和中等收入国家。此外，疫苗分发和储存方面的后勤挑战，尤其是在偏远地区，可能会阻碍市场成长。

由于错误讯息和缺乏认识而导致的疫苗犹豫也构成了重大挑战。解决这些问题需要政府、医疗保健提供者和组织共同努力，教育大众了解疫苗的益处和安全性。

脑膜炎双球菌疫苗市场的未来看起来充满希望，正在进行的研究和开发活动旨在提高疫苗功效和覆盖范围。针对其他血清群的新疫苗的推出以及通用疫苗的开发可能会彻底改变市场。政府、医疗机构和疫苗製造商之间的合作对于疫苗接种计画的成功实施至关重要。使疫苗更便宜、更容易获得的努力将在扩大市场覆盖范围方面发挥关键作用，特别是在发展中地区。

主要市场驱动因素

脑膜炎球菌疾病的发生率上升

疫苗开发的技术进步

主要市场挑战

公众意识和接受度

主要市场趋势

专注于联合疫苗

细分市场洞察

类型洞察

年龄层洞察

区域洞察

Global Meningococcal Vaccines Market was valued at USD 3.45 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.64% through 2029. The meningococcal vaccines market is primarily segmented based on vaccine type, including polysaccharide vaccines, conjugate vaccines, and combination vaccines. Among these, conjugate vaccines hold the largest market share due to their long-lasting immunity and ability to provide herd immunity. Combination vaccines are also gaining traction due to their convenience in immunization schedules, reducing the number of injections required.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 3.45 Billion
Market Size 2029	USD 4.74 Billion
CAGR 2024-2029	5.64%
Fastest Growing Segment	Combination
Largest Market	North America

Several factors are driving the growth of the meningococcal vaccines market. The foremost is the increasing prevalence of meningococcal diseases across the globe. Outbreaks in various regions have underscored the necessity for effective vaccination, prompting governments and health organizations to enhance immunization coverage.

Furthermore, technological advancements in vaccine development have led to the introduction of more effective and safe vaccines. Innovations such as protein-based vaccines and conjugate vaccines that cover multiple serogroups have significantly improved protection against meningococcal diseases. Additionally, the inclusion of meningococcal vaccines in national immunization programs in various countries has boosted market growth.

Despite the positive outlook, the meningococcal vaccines market faces several challenges. High costs associated with vaccine development and production can limit access, particularly in low- and middle-income countries. Additionally, logistical challenges in vaccine distribution and storage, especially in remote areas, can impede market growth.

Vaccine hesitancy, driven by misinformation and lack of awareness, also poses a significant challenge. Addressing these concerns requires concerted efforts from governments, healthcare providers, and organizations to educate the public about the benefits and safety of vaccines.

The future of the meningococcal vaccines market looks promising, with ongoing research and development activities aimed at improving vaccine efficacy and coverage. The introduction of new vaccines targeting additional serogroups and the development of universal vaccines could revolutionize the market. Collaborations between governments, healthcare organizations, and vaccine manufacturers are crucial for the successful implementation of vaccination programs. Efforts to make vaccines more affordable and accessible will play a key role in expanding market reach, particularly in developing regions.

Key Market Drivers

Rising Incidence of Meningococcal Disease

In recent years, the global healthcare landscape has witnessed a concerning uptick in the incidence of meningococcal disease, a potentially life-threatening bacterial infection caused by Neisseria meningitidis. This surge has significantly influenced the growth trajectory of the global meningococcal vaccines market. Meningococcal disease manifests in various forms, including meningitis and septicemia, both of which pose severe health risks and can lead to rapid deterioration without prompt medical intervention.

The increase in reported cases of meningococcal disease, particularly among adolescents and young adults, has spurred heightened awareness and proactive vaccination initiatives worldwide. This demographic group is particularly susceptible due to lifestyle factors and communal living situations, such as college dormitories and military barracks, which facilitate the spread of the bacteria.

According to statistics released by GOV.UK in January 2023, in England, the UK Health Security Agency (UKHSA) Meningococcal Reference Unit (MRU) confirmed 205 cases of IMD during the 2021-2022 period, marking a notable increase from the unusually low figure of 80 cases reported during 2020-2021, a period when COVID-19 pandemic restrictions were in effect. The incidence of IMD had decreased sharply by 83% in 2020-2021 compared to 463 confirmed cases in 2019-2020 and 531 confirmed cases in 2018-2019. The COVID-19 pandemic, along with the implementation of social distancing measures and lockdowns across the UK, significantly impacted the spread and detection of other infections, including IMD. Following the withdrawal of COVID-19 containment measures in England from July 2021, there has been a noticeable rise in overall case numbers.

Governments and healthcare authorities across the globe have responded by expanding immunization programs aimed at preventing outbreaks and reducing disease burden. This proactive approach not only aims to protect individuals but also to curtail healthcare costs associated with treating severe cases of meningococcal infection.

Furthermore, advancements in vaccine development and distribution have played a pivotal role in bolstering market growth. Modern meningococcal vaccines are formulated to target multiple strains of the bacteria, offering broader protection compared to earlier versions. The introduction of conjugate vaccines, which enhance immune response and duration of protection, has been particularly influential in shaping vaccination strategies and market dynamics.

The global meningococcal vaccines market is characterized by a competitive landscape with key players investing heavily in research and development to innovate new vaccine formulations. These efforts are aimed at addressing emerging strains and enhancing vaccine efficacy, safety, and accessibility across diverse demographics and geographic regions.

The global meningococcal vaccines market is poised for continued growth, supported by ongoing epidemiological surveillance, advancements in vaccine technology, and collaborative efforts between public health entities and vaccine manufacturers. The emergence of new vaccination recommendations and guidelines from health authorities is expected to further stimulate market demand and ensure widespread adoption of meningococcal vaccines globally.

Technological Advancements in Vaccine Development

In recent years, technological advancements have revolutionized vaccine development, significantly impacting the global Meningococcal Vaccines market. Meningococcal disease, caused by the bacterium Neisseria meningitidis, remains a serious public health concern worldwide, prompting continuous innovations in vaccine formulation and delivery. These advancements not only enhance vaccine efficacy and safety but also expand market opportunities through broader coverage and improved accessibility.

One of the key technological advancements driving the Meningococcal Vaccines market is the development of conjugate vaccines. Conjugate vaccines combine polysaccharides from the meningococcal bacteria with carrier proteins, which enhance the immune response, especially in infants and young children. This advancement has enabled broader protection against multiple serogroups of Neisseria meningitidis, addressing diverse epidemiological profiles globally.

In July 2023, MenFive, the inaugural conjugate vaccine aimed at safeguarding against the five primary causes of meningococcal meningitis in Africa, received prequalification from the World Health Organization (WHO). Developed over a span of 13 years through a partnership between Serum Institute of India Pvt. Ltd. (SIIPL) and PATH, with significant funding from the UK government's Foreign, Commonwealth and Development Office, MenFive provides protection against meningococcal serogroups A, C, W, Y, and X. It is designed to eradicate annual meningitis outbreaks and epidemics in the African meningitis belt-a region spanning 26 countries from Senegal and The Gambia in the west to Ethiopia in the east. Notably, MenFive is the sole vaccine capable of preventing meningitis caused by meningococcal group X, which has become increasingly associated with outbreaks in Africa.

Furthermore, advancements in recombinant DNA technology have facilitated the production of recombinant subunit vaccines. These vaccines contain specific antigens derived from the bacterium, eliminating the need to grow the pathogen itself. This approach not only improves vaccine safety by avoiding the use of live organisms but also streamlines manufacturing processes, ensuring consistent quality and scalability.

Innovations in adjuvant technology have also played a crucial role in vaccine development. Adjuvants are substances added to vaccines to enhance immune response, thereby reducing the required antigen dose and improving vaccine efficacy. Modern adjuvants enable the development of more potent vaccines with enhanced protective effects, contributing to higher immunization rates and greater market adoption.

Moreover, advancements in vaccine delivery systems have improved vaccine accessibility and compliance. Technologies such as microencapsulation and novel delivery routes (e.g., intranasal and transdermal) offer alternatives to traditional injections, reducing vaccine administration barriers and improving patient acceptance. These innovations are particularly beneficial in regions with limited healthcare infrastructure, facilitating widespread vaccine distribution and coverage.

The emergence of computational biology and bioinformatics has also accelerated vaccine development processes. These technologies enable researchers to predict antigenic epitopes, optimize vaccine formulations, and conduct virtual screening of candidate vaccines. This computational approach expedites vaccine design and development timelines, enabling faster response to emerging meningococcal strains and outbreaks.

Key Market Challenges

Public Awareness and Acceptance

In the realm of global healthcare, the Meningococcal Vaccines market faces a significant hurdle: public awareness and acceptance. Despite advancements in vaccine development and distribution, the effectiveness of these life-saving measures hinges heavily on community understanding and acceptance. This challenge is pivotal in shaping vaccination rates and ultimately impacting public health outcomes worldwide.

Public awareness serves as the cornerstone for vaccine uptake. Educating communities about the risks of meningococcal disease and the benefits of vaccination is crucial in fostering informed decision-making among individuals and caregivers. However, varying levels of awareness exist globally, influenced by factors such as cultural beliefs, access to healthcare information, and historical experiences with vaccines.

Misconceptions about vaccine safety and efficacy can deter individuals from seeking vaccination. Addressing misinformation through targeted educational campaigns is essential. In regions where meningococcal disease is uncommon, the perceived risk may be lower, leading to complacency regarding vaccination. Unequal access to healthcare services and vaccines, coupled with affordability concerns, can limit vaccine uptake, particularly in low-income communities. Cultural or religious beliefs may influence attitudes towards vaccination, necessitating culturally sensitive communication strategies.

Key Market Trends

Focus on Combination Vaccines

In the evolving landscape of healthcare, the global market for Meningococcal Vaccines is witnessing a significant trend towards the development and adoption of combination vaccines. These vaccines, which provide protection against multiple strains of meningococcal bacteria in a single formulation, are reshaping preventive healthcare strategies worldwide.

Combination vaccines simplify vaccination schedules by reducing the number of injections required. This convenience improves patient compliance, particularly among infants, children, and adolescents who are the primary target groups for meningococcal vaccination. By integrating multiple vaccines into one formulation, healthcare systems and providers can achieve cost savings through reduced procurement, storage, and administration expenses. This makes vaccination programs more economically feasible, especially in resource-constrained settings.

Meningococcal bacteria are known to exist in several serogroups (A, B, C, W, Y), each capable of causing severe illness. Combination vaccines often target multiple serogroups simultaneously, offering broader protection against a range of meningococcal strains in a single dose. The efficacy of combination vaccines in preventing meningococcal disease outbreaks is substantial. By reducing the transmission and prevalence of multiple serogroups, these vaccines contribute significantly to public health initiatives aimed at controlling and eliminating meningococcal infections.

Pharmaceutical companies are investing heavily in research and development to enhance the efficacy, safety, and compatibility of combination vaccines. This includes exploring new antigen combinations and delivery technologies to optimize vaccine performance. Regulatory bodies play a crucial role in evaluating and approving combination vaccines for safety and efficacy. Streamlined regulatory pathways for combination products encourage innovation and expedite market entry, driving competition and product availability. Manufacturers are expanding their market reach to ensure broad accessibility of combination vaccines, particularly in regions with high meningococcal disease burden and limited healthcare resources. Collaborations with international health organizations and governments facilitate vaccine distribution and adoption.

Segmental Insights

Type Insights

Based on Type, Combination have emerged as the fastest growing segment in the Global Meningococcal Vaccines Market in 2023. Combination vaccines offer enhanced convenience and efficiency in vaccination schedules. By consolidating protection against different meningococcal serogroups or other diseases into one injection, healthcare providers can streamline immunization programs. This approach not only simplifies logistics but also reduces the number of clinic visits required for complete protection, thereby improving patient compliance and overall vaccination coverage rates.

The complexity of meningococcal disease, which encompasses several serogroups (A, B, C, W, Y, etc.), underscores the value of combination vaccines. Each serogroup poses distinct epidemiological challenges across different regions and populations. Combination vaccines that target multiple serogroups in a single dose address this complexity comprehensively, offering broader protection against the diverse strains responsible for meningococcal infections globally.

The economic rationale behind combination vaccines is compelling. By reducing the need for separate vaccinations against each meningococcal serogroup, healthcare systems can achieve cost savings in procurement, distribution, and administration. This cost-effectiveness is particularly significant in resource-constrained settings and emerging markets where optimizing healthcare expenditure while ensuring broad vaccine coverage is a priority.

Combination vaccines contribute to vaccine hesitancy mitigation efforts. Simplified vaccination schedules and reduced needle pricks can enhance patient acceptance and confidence in immunization programs. This factor is crucial in overcoming barriers to vaccine uptake and achieving high population immunity against meningococcal disease, thereby preventing outbreaks and reducing disease burden.

Age Group Insights

Based on Age Group, Children & Adult have emerged as the dominating segment in the Global Meningococcal Vaccines Market during the forecast period. Meningococcal disease can affect individuals of all ages, with infants, young children, adolescents, and adults all susceptible to varying degrees. Children, especially infants, have historically been a primary focus due to their higher risk of infection and severe outcomes. Vaccination efforts in pediatric populations aim to provide early protection against meningococcal strains.

National immunization programs globally prioritize childhood vaccinations, including meningococcal vaccines. This focus ensures high vaccination coverage among children, reducing disease incidence and transmission within communities. These programs are instrumental in shaping market demand and driving vaccine adoption among younger demographics.

Many countries mandate meningococcal vaccination for school entry or college enrollment, particularly for adolescents and young adults. These requirements stem from the potential for outbreaks in crowded settings such as schools and dormitories, highlighting the importance of vaccination to prevent disease spread among this age group.

Travel-related policies often recommend or require meningococcal vaccination, particularly for individuals visiting regions with high disease prevalence or during periods of increased transmission. This guidance targets both adults and children, ensuring comprehensive protection against meningococcal strains encountered during travel.

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Meningococcal Vaccines Market in 2023. At the forefront of vaccine innovation, North American pharmaceutical companies and research institutions boast robust capabilities in developing and refining Meningococcal Vaccines. These entities leverage state-of-the-art research facilities, cutting-edge technologies, and a strong regulatory framework to accelerate vaccine development timelines and ensure compliance with stringent safety and efficacy standards. This proactive approach positions North America as a pivotal contributor to global vaccine advancements.

North America's well-established healthcare infrastructure plays a pivotal role in facilitating widespread vaccine adoption and distribution. The region benefits from a network of healthcare providers, vaccination clinics, and public health agencies that collaborate seamlessly to promote immunization campaigns. This infrastructure not only ensures timely access to Meningococcal Vaccines but also supports comprehensive healthcare delivery systems capable of managing disease outbreaks effectively.

A culture of vaccination advocacy and public health awareness prevails across North America, contributing to high vaccine uptake rates among the population. Educational initiatives, supported by healthcare professionals and government agencies, emphasize the importance of immunization in preventing meningococcal disease. This concerted effort fosters a proactive approach to public health, wherein individuals and caregivers prioritize vaccination as a preventive measure against infectious diseases.

North American pharmaceutical companies forge strategic partnerships with international organizations, governments, and non-profit entities to extend their market reach and influence in the global healthcare landscape. These collaborations facilitate the distribution of Meningococcal Vaccines to regions with high disease prevalence or limited healthcare resources, thereby expanding market penetration and addressing unmet medical needs on a global scale.

Key Market Players

Sanofi S.A.

Merck & Co., Inc.

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Pfizer, Inc.

Walwax Biotechnology Co., Ltd

Report Scope:

In this report, the Global Meningococcal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Meningococcal Vaccines Market, By Type:

Conjugate Polysaccharide Combination Others

Meningococcal Vaccines Market, By Age Group:

Infant Children & Adult

Meningococcal Vaccines Market, By Region:

United States
Canada
Mexico

France
United Kingdom
Italy
Germany
Spain

China
India
Japan
Australia
South Korea

Brazil
Argentina
Colombia

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Meningococcal Vaccines Market.

Available Customizations:

Global Meningococcal Vaccines Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Meningococcal Vaccines Market

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Type
5.5. Breakdown of Pipeline, By Age Group
5.6. Clinical Trials Heat Map

6. Global Meningococcal Vaccines Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type (Conjugate, Polysaccharide, Combination, Others)
- 6.2.2. By Age Group (Infant, Children & Adult)
- 6.2.3. By Region
- 6.2.4. By Company (2023)
6.3. Market Map

7. Asia Pacific Meningococcal Vaccines Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Age Group
- 7.2.3. By Country
7.3. Asia Pacific: Country Analysis
- 7.3.1. China Meningococcal Vaccines Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Age Group
- 7.3.2. India Meningococcal Vaccines Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Age Group
- 7.3.3. Australia Meningococcal Vaccines Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Age Group
- 7.3.4. Japan Meningococcal Vaccines Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Age Group
- 7.3.5. South Korea Meningococcal Vaccines Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Age Group

8. Europe Meningococcal Vaccines Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Age Group
- 8.2.3. By Country
8.3. Europe: Country Analysis
- 8.3.1. France Meningococcal Vaccines Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Age Group
- 8.3.2. Germany Meningococcal Vaccines Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Age Group
- 8.3.3. Spain Meningococcal Vaccines Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Age Group
- 8.3.4. Italy Meningococcal Vaccines Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Age Group
- 8.3.5. United Kingdom Meningococcal Vaccines Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Age Group

9. North America Meningococcal Vaccines Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Age Group
- 9.2.3. By Country
9.3. North America: Country Analysis
- 9.3.1. United States Meningococcal Vaccines Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Age Group
- 9.3.2. Mexico Meningococcal Vaccines Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Age Group
- 9.3.3. Canada Meningococcal Vaccines Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Age Group

10. South America Meningococcal Vaccines Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Age Group
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Meningococcal Vaccines Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Age Group
- 10.3.2. Argentina Meningococcal Vaccines Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Age Group
- 10.3.3. Colombia Meningococcal Vaccines Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Age Group

11. Middle East and Africa Meningococcal Vaccines Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Type
- 11.2.2. By Age Group
- 11.2.3. By Country
11.3. MEA: Country Analysis
- 11.3.1. South Africa Meningococcal Vaccines Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Type
    - 11.3.1.2.2. By Age Group
- 11.3.2. Saudi Arabia Meningococcal Vaccines Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Type
    - 11.3.2.2.2. By Age Group
- 11.3.3. UAE Meningococcal Vaccines Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Type
    - 11.3.3.2.2. By Age Group

12. Market Dynamics

12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions

14. Global Meningococcal Vaccines Market: SWOT Analysis

15. Porter's Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product

16. Competitive Landscape

16.1. Sanofi S.A.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
16.2. Merck & Co., Inc.
16.3. GlaxoSmithKline plc
16.4. Serum Institute of India Pvt. Ltd.
16.5. Pfizer, Inc.
16.6. Walwax Biotechnology Co., Ltd

17. Strategic Recommendations

18. About Us & Disclaimer

02-2729-4219

+886-2-2729-4219

License/价格

脑膜炎双球菌疫苗市场 - 全球产业规模、份额、趋势、机会和预测，按类型（结合物、多醣、组合、其他）、年龄组（婴儿、儿童和成人）、地区和竞争细分，2019-2029F

Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate, Polysaccharide, Combination, Others), By Age Group (Infant, Children & Adult), By Region and Competition, 2019-2029F

主要市场驱动因素

主要市场挑战

主要市场趋势

细分市场洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：COVID-19 对全球脑膜炎双球菌疫苗市场的影响

第 5 章：临床试验分析

第 6 章：全球脑膜炎双球菌疫苗市场展望

第 7 章：亚太地区脑膜炎双球菌疫苗市场展望

第 8 章：欧洲脑膜炎双球菌疫苗市场展望

第 9 章：北美脑膜炎双球菌疫苗市场展望

第 10 章：南美洲脑膜炎双球菌疫苗市场展望

第 11 章：中东和非洲脑膜炎双球菌疫苗市场展望

第 12 章：市场动态

第 13 章：市场趋势与发展

第 14 章：全球脑膜炎双球菌疫苗市场：SWOT 分析

第 15 章：波特的五力分析

第16章：竞争格局

第 17 章：策略建议

第18章调查会社について・免责事项

Key Market Players

Report Scope:

Meningococcal Vaccines Market, By Type:

Meningococcal Vaccines Market, By Age Group:

Meningococcal Vaccines Market, By Region:

Competitive Landscape

Available Customizations:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Meningococcal Vaccines Market

5. Clinical Trial Analysis

6. Global Meningococcal Vaccines Market Outlook

7. Asia Pacific Meningococcal Vaccines Market Outlook

8. Europe Meningococcal Vaccines Market Outlook

9. North America Meningococcal Vaccines Market Outlook

10. South America Meningococcal Vaccines Market Outlook

11. Middle East and Africa Meningococcal Vaccines Market Outlook

12. Market Dynamics

13. Market Trends & Developments

14. Global Meningococcal Vaccines Market: SWOT Analysis

15. Porter's Five Forces Analysis

16. Competitive Landscape

17. Strategic Recommendations

18. About Us & Disclaimer